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Abstract
The frequency of some Cystic Fibrosis (CF) Transmembrane Conductance Regulator gene (CFTR) mutations varies between
populations. Genetic testing during newborn screening (NBS) for CF can identify less common mutations with low clinical expression
in childhood and previously considered mild but not fully characterized, such as the mutation p.Val232Asp (c.695T>A). The aim of
this study was to describe CF patients with the V232D mutation. We identify CF children with the V232D mutation detected by NBS
and compare them with CF adults with this mutation whose diagnosis was prompted by clinical symptoms in the same period. We
studied clinical, biochemical, spirometric, and prognostic features in both populations. NBS program tested 276,523 children during
a period of 14 years (2003–2017) and identified 54 cases of CF. Six children (11%) had the V232Dmutation. Over the same period, 5
adults (age 37.6±16.29 years old) with symptoms of CF and this mutation were also diagnosed. Follow-up duration was mean 10.1
years for adults and mean 6.5 years for children. In the adult group, lung function was impaired at diagnosis in all patients (Forced
Expiratory Volume1—FEV1—67.12%±13.09) and worsened in children tested during evolution (FEV1first: 113%; FEV1last: 64%).
Pancreatic insufficiency was present in adult group, with recurrent pancreatitis in 1 present. Although with less clinical expression in
children, V232D is associated with pulmonary and pancreatic involvement during adulthood and CF cannot be considered mild. This
mutation is present in 11% of all patients diagnosed with CF in our region. Its inclusion in some NBS programs should be taken into
account in order to improve the prognosis of affected children.
Abbreviations: BMI= bodymass index, CF= cystic fibrosis, CFTR= cystic fibrosis transmembrane conductance regulator gene,
CFTR1 = Cystic Fibrosis Mutation Database, CFTR2 = Clinical and Functional Translation of CFTR Database, FEV1 = forced
expiratory volume at first second, IRT = immunoreactive trypsinogen, NBS = newborn screening, TM = transmembrane segment.
Keywords: CFTR, genetic testing, lung function, newborn screening, pancreatic insufficiency[1]1. Introduction
The cystic fibrosis (CF) transmembrane conductance regulator
gene (CFTR; MIM no. 602421) consists of 27 exons, spanningEditor: Yan Li.
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approximately 250kb on 7q31.2, and encodes an anion
transporter protein in the epithelium. This protein forms a
chloride channel pore that plays a role in chlorine and bicarbonate
transport[2] and has secondary effects on sodium transport. Its
dysfunction leads to increased salt concentration in sweat and
thickened secretions in various organ systems. To date, more than
1700 mutations and polymorphisms have been identified
throughout the CFTR gene. The list of mutations is continuously
updated in the CFMutation Database (CFTR1)[3] and the Clinical
and Functional Translation of CFTR database (CFTR2).[4] The
most common CFTR mutation is F508del, which accounts for
approximately 75% of all CFTR alleles in patients with CF. Its
prevalence decreases as on moves from northwest to southeast
Europe.[5] The remaining 25%ofCFTR alleles are heterogeneous.
In the CFTR1 database,[3] missense mutations account for 42%of
all alleles, frameshift mutations for 15%, splicing mutations for
12%, nonsense mutations for around 10%, inframe insertions/
deletions for 2%, large insertions/deletions for 3%, promoter
mutations for 0.5%, and sequence variations not predicted to be
disease-causing for 15%.
The frequency and distribution of CFTR mutations vary
among populations. Very few mutations have a worldwide
frequency above 0.1%,[5] but it is important to identify the
correlation with symptoms or clinical expression.
Early detection of CF by newborn screening (NBS) enables the
establishment of preventive measures and treatment before the
onset of irreversible changes in the respiratory tract or other
complications. NBS protocols vary across countries and the cost-
effectiveness has been debated.[6] Protocols generally combined a
Fernández-Lorenzo et al. Medicine (2018) 97:28 Medicinefirst-tier strategy consisting of immunoreactive trypsinogen (IRT)
testing with cutoffs at the 96th and 99.5th percentiles and a
second-tier strategy consisting of a second IRT, pancreatic-
associated protein testing or CFTR mutation analysis. CFTR
mutation panels have also been proposed as third-tier test.
Genetic testing during NBS can identify less common mutations
that may have little clinical relevance in childhood but can cause
lung and pancreatic problems later. The inclusion of these
mutations in NBS programs could improve the prognosis of
the disease in affected children.[7,8]
The broad phenotypic spectrum of CF is not explained by
obvious genotype-phenotype correlations[5], and multiple addi-
tive effects may be responsible for CFTR-related disorders.[9]
However, some mutations have been considered related to mild
CF, but its phenotype has not been fully described and the
frequency can be high in some regions. One such example is the
p.Val232Asp (c.695T>A) mutation, not included in CFTR2
database despite being listed in CFTR1 and considered so far to
cause mild CF.
The aim of this study is to characterize the clinical,
biochemical, spirometric, and prognosis features of CF patients




The study population comprised children and adults with CF
carrying the V232D mutation. The children were identified by
NBS and the adults were diagnosed following genetic testing
prompted by clinical symptoms of CF and abnormal sweat
chloride test. The period of the study was from January of 2003
to December of 2017.
The following data were evaluated at diagnosis: sex, age at
diagnosis, geographic origin, family history of CF, CFTR
mutations in the other allele, sweat chloride levels, pulmonary
colonization, and lung and pancreatic function. Follow-up test
included anthropometric measurements, spirometry (percent of
predicted forced expiratory volume in the first second—FEV1%),
and biochemical tests including measurement of fat-soluble
vitamin levels. Follow-up duration was mean 10.1 years for
adults and mean 6.5 years for children.
The study was approved by the local ethics committee and
informed consent was obtained from all patients and/or from
their parents.
2.2. Analytical and anthropometric tests
NBS for CF was performed using dried blood samples collected
for routine NBS. The first tier in the protocol was IRT with a
standard cutoff of 70ng/mL (this cutoff is calculated every day
according to batch results). All patients with high IRT levels
confirmed in a second batch underwent CFTR genetic analysis.
DNA was isolated using standard protocols from blood
samples obtained from all patients and their parents in the case of
children. Analysis of CFTRmutations was performed using mass
spectrometry (Sequenom Inc, San Diego, CA) following an in-
house assay using the SequenomMassARRAY iPLEX system.[10]
For carrier detection of V232D CFTR mutation, the exon 6a of
the CFTR gene was amplified by polymerase chain reaction using
the forward primer 50-CTATGCATAGAGCAGTCCTG, and the
reverse primer 50-TTAGTGTGCTCAGAACCACG, with the
following program: 2minutes at 95 °C, 35 cycles of 60seconds at2
94 °C, 60seconds at 55 °C, 60seconds at 72 °C, and finally
7minutes at 72 °C. Sequencing reactions were run using the
same primers and the Big Dye Terminator v3.1 Kit (Applied
Biosystems, Foster City, CA) and the products analyzed on an
ABI 3730XL capillary sequencer.
Nutritional status was assessed with the body mass
index (BMI), calculated as weight (kg)/height squared (m2),
and Shukla Index, calculated as (actual weight [kg]/actual height
[m])/(50th percentile weight/50th percentile height)100
using the World Health Organization growth standards as a
reference.[11]
For the sweat chloride test, sweat was induced by pilocarpine
iontophoresis and chloride concentration was measured on the
Sweat Chloride Analyzer (Advanced Instruments, Inc., Nor-
wood, MA) as previously described.[12] Lung function was
evaluated by spirometry in adults and older children according to
reference procedures.[13] Pancreatic function was investigated
using the fecal pancreatic elastase enzyme-linked immunosorbent
assay kit (Bioserv Diagnostics, Rostock, Germany), with normal
value set at >200mg elastase/g stool. Vitamin levels were
determined by high-pressure liquid chromatography (Bio Rad,
Hercules, CA). Normal values for children: vitamin D 20 to 100
ng/mL; vitamin A 0.2 to 0.49mg/L; vitamin E 3.00 to 15.00mg/
mL. Normal values for adults: vitamin D 20 to 100ng/mL;
vitamin A 0.3 to 0.8mg/L; vitamin E 5.00 to 18.98mg/mL.3. Results
A total of 276,523 newborns were included in NBS program
from 2003 to 2017. During this period, 54 patients with positive
genetic study were identified (Fig. 1). Six patients presented with
high IRT levels and 2 CFTR mutations in both alleles, one of
which was V232D. One patient moved to another country, so 5
patients were included in the study (Table 1). Over the same
period, the V232Dmutation was detected in 5 adult patients with
varying clinical symptoms of CF and elevated sweat chloride
levels (Table 2). All the patients were Caucasian. We divided the
patients into 2 groups: adults diagnosed on the basis of typical
symptoms (classic CF) and children diagnosed by NBS
(asymptomatic CF at diagnosis).
3.1. Adults with clinical symptoms
The 5 adult patients with CF and the V232D mutation were
diagnosed at a mean age of 37.6±16.29 years old (median 33.0,
range 26–66) (Table 2). CF had been suspected because of
pulmonary disease in 4 cases. The fifth patient was tested because
she had a sibling with CF. A family history of CF was common: 2
of the patients were siblings (patients 1 and 2) and a third had a
cousin with CF (patient 5). Mutation analysis of the other
allele revealed 4 different mutations. The F508del mutation
was detected in just 1 patient (patient 5). Mean±SD sweat
chloride concentrations were 87±21.94mEq/L (median 81.0,
range 63–110).
The 4 symptomatic patients had bronchiectasis at the time of
diagnosis and were colonized by several opportunistic agents.
Lung function was also impaired in the asymptomatic patient
(patient 4). Mean FEV1% at diagnosis was 67.12%±13.09
(median 71.4, range 44–77, normal parameter for adults ≥80%).
Patient 4 had undergone a left upper lobectomy for a lung abscess
and patient 3 had undergone radiofrequency turbinate reduction.
The patient with the worst lung function is currently being
evaluated for a lung transplant (patient 3).
Figure 1. Cystic fibrosis mutations detected by newborn screening in Galicia, Spain (2003–2017).
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1 F 6 6.7 c.1521_1523delCTT/
c.695T>A
68 80 116 >500 40.5 0.35 17.0 16.4 (0.37) 15.3 (0.22) 102.6 100.2





>500 27.0 0.27 10.8 17.7 (1.22) 19.3 (1.91) 125.0 128.2
3 M 23 5.0 c.1519_1521delATC/
c.695T>A
92 92 114 385 107.9 0.18 11.9 16.6 (0.51) 16.2 (0.53) 100.1 103.9




113 64 >500 57.0 0.23 11.2 16.7 (0.52) 18.4 (0.48) 110.6 92.5
5 F 3 3.0 c.579+1G>
T /c.695T>A
101 99 >500 40.0 0.30 10.7 14.1 (1.99) 18.1 (1.03) 105.2 107.4
BMI = body mass index, F = female, FEV1 = forced expiratory volume at first second, IRT = immunoreactive trypsinogen, M = male, SNI = Shukla Nutritional Index (actual weight [kg]/actual height [m])/(weight
P50/height P50)100.
∗
Normal values: FEV1≥80%; elastase >200mg/g; fecal fat <2.00g/24h; vitamin D 20–100ng/mL; vitamin A 0.2–0.49mg/L; vitamin E 3.00–15.00mg/mL.
Table 2






































71.4 78.8 500 23 0.42 13.2 19.0 (1.02) 19.0 (1.02) Bronchiectasis+
pancreatitis




73.3 59.1 500 37 0.36 12.1 18.6 (1.23) 19.6 (0.76)





44.2 36.0 78 28 0.40 16.6 27.8 (1.23) 27.4 (1.18) Bronchiectasis+pancreatitis+
radiofrequency turbinate+
severe respiratory failure




77.0 86.0 225 9 0.45 19.3 28.2 (1.26) 29.0 (1.39) Bronchiectasis+
left upper lobectomy




69.7 77.1 500 11 0.29 13.4 21.8 (0.01) 21.8 (0.01) Bronchiectasis
BMI = body mass index, CF = cystic fibrosis, F = female, FEV1 = forced expiratory volume at first second, M = male.
∗
Normal values: FEV1≥80%; elastase >200mg/g; fecal fat <7.00g/24h; vitamin D 20–100ng/mL; vitamin A 0.3–0.8mg/L; vitamin E 5.00–18.98mg/mL.
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Fernández-Lorenzo et al. Medicine (2018) 97:28 MedicineTwo patients (4 and 5) had positive fecal fat values, and
recurrent pancreatitis was present in 1 patient despite pancreatic
insufficiency (elastase level <200mg/g stool). All patients had
adequate vitamin E levels (mean 14.9±2.6mg/mL, median 13.4,
range 12.1–19.3); and variable vitamin D (mean 21.6±10.5ng/
mL, median 23, range 9–37) and vitamin A levels (mean 0.38±
0.06mg/L, median 0.40, range 0.29–0.45). There was no
evidence of malnutrition. The BMI Z-score was above normal
in 2 patients (3 and 4) and within the normal range in other 3.3.2. Children diagnosed by NBS
Three of the 5 children with CF detected by NBS were girls and 2
were boys. Their mean age at genetic diagnosis was 7.2±8.9
months (median 3.0, range 2.0–23.0). Their mean current age is
7.1±2.9 years (median 6.9, range 3.2–12.2). Two of the children
were siblings (patients 4 and 5). There was no other relevant
family history. IRT levels were high in all cases duringNBS (mean
87.6±14.9ng/mL, median 92, range 68–101). The mutation
analysis of the other allele of the CFTR gene showed genetic
variability, with detection of F508del, 711+1G-T, G542X, and
I507del. All the patients had elevated sweat chloride levels (mean
93.8±8.32mEq/L, median 98, range 80–100).
Because of children’s age, we were only able to obtain
spirometry in 3 patients. The results of FEV1 in younger children
were into normal values (116% patient 1 and 114% patient 3).
The older child (patient 4) showed worsening of lung function,
with first FEV1 113% and last test with FEV1 64%, during a
period of time of 4.2 years (normal parameter at this age ≥80%).
This patient is also currently colonized by Staphylococcus aureus.
A second patient is colonized by Streptococcus pyogenes and
Candida albicans (patient 2).
All the children had normal vitamin A levels (mean 0.26±0.07
mg/L, median 0.27, range 0.18–0.35). Vitamin E levels were
within the upper limit of normal, with a mean value of 12.3±
2.6mg/mL (median 11.2, range 10.7–17). Vitamin D levels were
near 30ng/mL in all patients (mean 54.5±31.7, median 40.5,
range 27–107). Pancreatic function was normal in all children
and consequently no patient had positive values of fecal fat. The
current Shukla Index score is similar to that at diagnosis (106.4%
vs 108.7%). Four of the patients are within normal limits and 1
has mild obesity (patient 2) (index 120% at diagnosis and 128%
at present).4. Discussion
This study analyzed clinical, biochemical, spirometric, and
prognostic features of CF in a group of patients heterozygous
for the V232D mutation detected by NBS or genetic testing
prompted by clinical symptoms. Our findings shed light on factors
that could potentially influence the inclusion of this mutation in
NBS programs, such as clinical outcomes during adulthood.
NBS programs across Spain include screening for CF. In our
region, NBS for CF started in 2003 and until 2017 had identified
25 cases of CF (1:11,061), 16 cases of inconclusive CF
(1:17,283), and 13 cases of CFTR-related diseases, with a wide
variability of mutations. V232Dmutation was detected in 6 of 54
positive results for CF. This corresponds to 11% of all patients
diagnosed with CF by NBS between 2003 and 2017. Overall, the
V232D mutation is carried by 10 patients, which based on the
total number of patients with CF in our region (n=105),
corresponds to a prevalence rate of 9.5%.4
According to a study published by Alonso et al in 2006 in
the CFTR gene in patients of Spanish ancestry, this mutation
presented with a frequency of 0.71% (n=1954). A national
monograph on CF published in 2005[15] described a prevalence
of 0.51% for V232D in 780 Spanish families with CF. The
frequency observed in our series suggests a higher prevalence of
this mutation in northwest Spain. Familial aggregation factor (a
pair of siblings in each group with exactly the same mutations)
and a geographical location (all the adult patients were from 2
local areas) may of course have an important role in the observed
frequency.
The V232D mutation has been previously described in the
Brazilian population. In a study published in 2000, molecular
analyses of 160 Brazilian CF patients with CF detected the
mutation in 1 patient (0.62%), who also had the R334W
mutation.[16] This association was not detected in our series. A
more recent study of 37 patients with suspected CF in Brazil
reported 2 cases of CFwith the V232Dmutation (5.4%).[17] Both
patients had F508del in the other allele.
Regarding the frequency and clinical relevance of CF
mutations, the V232D mutation has been described in more
than 0.1% of CFTR mutations in the Spanish CF population
and the Hispanic CF population in the USA.[5] According to
the Exome Aggregation Consortium (http://exac.broadinstitute.
org/).[18] However, this variant is only present in one of 33,364
European reference samples (1.499e05 population frequency).
Despite the scarcity of information on V232D in CF databases (it
is not listed in CFTR2, for example), our findings show that this
mutationmust be considered a CF causingmutation and included
in some NBS programs.
The V232D mutation involves a change from a neutral residue
(Valine) to a polar residue (aspartic acid) that affects the fourth
transmembrane segment (TM4) of the CFTR protein. It has been
hypothesized that the aspartate residue forms a non-native
hydrogen bond with Gln207 in TM3 to disrupt interactions
between TM3 and TM4.[19] However, a more recent study[19]
suggested that V232D might inhibit maturation of the protein
through a mechanism of misfolding, that is, it appears that the
V232D mutation introduces a hydrophilic residue into a
hydrophobic pocket trapping the protein. This partially folded
intermediate can be efficiently rescued with correctors.[20]
Although V232D may be specific to certain geographic areas
and population groups, it cannot be considered “mild.” All the
adult patients in our series had impaired respiratory function and
colonization by resistant microorganisms and such conditions
cannot be considered typical of a mild mutation.[5,6,21,22]
Between 10%and 50%of patients with idiopathic bronchiectasis
have a CFTR mutation,[23] and in our series, CF studies were
performed because of differential diagnosis of bronchiectasis in 4
of 5 adult patients.[24,25]
Lung disease in CF becomes more evident with age, but clinical
and tests data suggest that it starts in early life. Two of the adults
in our series (patients 3 and 4) had “nasal problems”[26] in
childhood and the only child old enough to undergo various
spirometries had impaired respiratory function before 5 years
old. The detection of the V232D mutation by NBS in our
population enables CF to be diagnosed before the onset of clinical
manifestations and lung damage. Other studies of uncommon CF
mutations[27] that go undetected by conventional screening have
shown a similar clinical pattern (nasal problems in early life,
severe bronchiectasis and colonization by resistant microorgan-
isms). Studies specifically analyzing the V232D mutation,
Fernández-Lorenzo et al. Medicine (2018) 97:28 www.md-journal.comhowever, have not described the pulmonary status of
patients.[16,17]
Pancreatic involvement in CF can present in different forms,
and it is more common with certain genetic patterns.[28–30] In a
study of Brazilian population,[16] the V232D mutation was
largely associated with pancreatic sufficiency, but the few other
studies that have analyzed this mutation unfortunately did not
describe pancreatic function. In our series, all the children had
adequate pancreatic function, and one of the adults had
pancreatic insufficiency. Recurrent acute pancreatitis, however,
was observed in 2 adults, including the patient with pancreatic
insufficiency. Acute pancreatitis has been reported in CF patients
with pancreatic insufficiency,[31] although recurrent pancreatitis
is more common in CF patients with adequate function.[32] Our
results are consistent with reports in the literature that 20% of
pancreatic-sufficient patients have chronic or recurrent acute
pancreatitis which can progress to pancreatic insufficiency as a
result of inflammatory injury.[33] The normal pancreatic function
observed in almost all the patients in our series could explain why
we detected no cases of malnutrition or vitamin deficiency.
Our study has some limitations. First, we have described a series
of cases from a specific geographic region. Considering, however,
the high frequency of this mutation in our community and the
scarce data available on the V232D mutation, our description is
relevant. Second,becauseof the children’s age,wewereonly able to
study lung function in 3 of the 5 patients diagnosed by NBS.
Nevertheless, inclusion of the V232D mutation in the NBS
protocol enabled early diagnosis and treatment before the onset of
clinical manifestations and worsening of lung function.
In summary, we have described a series of adult and pediatric
CF patients carrying the V232D mutation in which all the adults
and 1 child had lung impairment. The high prevalence of this
mutation in our population and the phenotype of pulmonary
disease are important considerations. Description of genetic CF
patterns and phenotypes in specific geographic areas can help to
improve NBS programs and early diagnosis with the prognostic
repercussion that this can imply.Author contributions
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